Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy

Hepatology International

Volumn 7, Issue 1, 2013, Pages 162-170

  Chen, Chun Hao ^a,b   Huang, Jee Fu ^a,c   Huang, Chung Feng ^a,d,e   Yeh, Ming Lun ^e   Yang, Jeng Fu ^e   Hsieh, Ming Yen ^a,d,e   Hou, Nai Jen ^c   Lin, Zu Yau ^a,e   Chen, Shinn Cherng ^a,e   Hsieh, Ming Yuh ^a,e   Wang, Liang Yen ^a,e   Chuang, Wan Long ^a,e   Dai, Chia Yen ^a,e   Yu, Ming Lung ^a,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MUNICIPAL UNITED HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alanine aminotransferase; Discrepancy; HCV; Steatosis; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGING; ARTICLE; BIOCHEMICAL RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGICAL RESPONSE; VIRUS LOAD;

EID: 84875262688     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9388-x     Document Type: Article

References (32)

1. ML Yu WL Chuang 2009 Treatment of chronic hepatitis C in Asia: when East meets West J Gastroenterol Hepatol 24 336 345 19335784 10.1111/j.1440-1746.2009. 05789.x 1:CAS:528:DC%2BD1MXltFCgtL8%3D
2. ML Yu CY Dai JF Huang, et al. 2008 Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial Hepatology 47 1884 1893 18508296 10.1002/hep.22319 1:CAS:528: DC%2BD1cXotVagtro%3D
3. ML Yu CY Dai JF Huang, et al. 2007 A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C Gut 56 553 559 16956917 10.1136/gut.2006.102558 1:CAS:528: DC%2BD2sXks1Giu7g%3D
4. CH Hung CM Lee SN Lu, et al. 2002 Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol 17 1307 1311 12423276 10.1046/j.1440-1746.2002.02874.x 1:CAS:528:DC%2BD38Xpsl2ms7w%3D
5. JY Lau M Mizokami T Ohno, et al. 1993 Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C Lancet 342 1208 1209 7901531 10.1016/0140-6736(93)92187-X 1:STN:280:DyaK2c%2FkvVKmsw%3D%3D
6. LM Blatt MJ Tong JG McHutchison, et al. 1998 Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers J Interferon Cytokine Res 18 75 80 9506457 10.1089/jir.1998.18.75 1:CAS:528:DyaK1cXhtlWrtLg%3D
7. N Marino PL Blanc C Ble P Pierotti F Mazzotta 2003 Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin J Biol Regul Homeost Agents 17 205 206 14518725 1:CAS:528:DC%2BD3sXptFKisbY%3D
8. H Okamoto H Tokita M Sakamoto, et al. 1993 Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection J Gen Virol 74 Pt 11 2385 2390 7504073 10.1099/0022-1317-74-11-2385 1:CAS:528:DyaK2cXhvVChtr8%3D
9. RG Knodell KG Ishak WC Black, et al. 1981 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 431 435 7308988 10.1002/hep.1840010511 1:STN:280:DyaL38%2FnsVagsA%3D%3D
10. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13:372-374
11. VJ Desmet M Gerber JH Hoofnagle M Manns PJ Scheuer 1994 Classification of chronic hepatitis: diagnosis, grading and staging Hepatology 19 1513 1520 8188183 10.1002/hep.1840190629 1:STN:280:DyaK2c3ksFWisw%3D%3D
12. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 343:1666-1672
13. KL Lindsay C Trepo T Heintges, et al. 2001 A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 395 403 11481625 10.1053/jhep.2001.26371 1:CAS:528:DC%2BD3MXmtVGqtLs%3D
14. N Kumagai S Kuramochi 1994 Correlation between histological features of liver biopsy specimens and clinical effect of interferon on patients with chronic hepatitis C Nippon Rinsho 52 1769 1773 7521416 1:STN:280: DyaK2czlvFSgtA%3D%3D
15. A Kozlowski SA Charles JM Harris 2001 Development of pegylated interferons for the treatment of chronic hepatitis C BioDrugs 15 419 429 11520253 10.2165/00063030-200115070-00001 1:CAS:528:DC%2BD3MXmvFOjtLs%3D
16. M Basso EG Giannini F Torre, et al. 2009 Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse Hepatology 49 1442 1448 19350657 10.1002/hep.22810 1:CAS:528:DC%2BD1MXlslKmtbg%3D
17. CY Dai JF Huang MY Hsieh WL Chuang ML Yu 2010 Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection Gut 59 418 20207653 10.1136/gut.2009.199224
18. JF Huang ML Yu CY Dai, et al. 2008 Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection Am J Gastroenterol 103 1933 1940 18637090 10.1111/j.1572-0241.2008.01996.x 1:CAS:528:DC%2BD1cXhtFGhur3K
19. CY Dai WL Chuang CK Ho, et al. 2008 Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study J Hepatol 49 9 16 18486265 10.1016/j.jhep.2008.03.016 1:CAS:528: DC%2BD1cXmvFelsL8%3D
20. D Prati ML Shiffman M Diago, et al. 2006 Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C J Hepatol 44 679 685 16487620 10.1016/j.jhep.2006.01.004 1:CAS:528: DC%2BD28XisFyqt7k%3D
21. PH Thurairajah D Thorburn S Hubscher, et al. 2007 Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C Aliment Pharmacol Ther 25 1293 1300 17509097 10.1111/j.1365-2036.2007.03322.x 1:CAS:528: DC%2BD2sXot1Ckur4%3D
22. E Bjornsson P Angulo 2007 Hepatitis C and steatosis Arch Med Res 38 621 627 17613353 10.1016/j.arcmed.2006.09.001
23. JJ Feld JH Hoofnagle 2005 Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 967 972 16107837 10.1038/nature04082 1:CAS:528:DC%2BD2MXotFent7c%3D
24. JR Larrubia S Benito-Martinez J Miquel-Plaza, et al. 2009 Cytokines-their pathogenic and therapeutic role in chronic viral hepatitis Rev Esp Enferm Dig 101 343 351 19527080 10.4321/S1130-01082009000500006 1:CAS:528: DC%2BD1MXpt1Slur4%3D
25. MY Sheikh J Choi I Qadri JE Friedman AJ Sanyal 2008 Hepatitis C virus infection: molecular pathways to metabolic syndrome Hepatology 47 2127 2133 18446789 10.1002/hep.22269 1:CAS:528:DC%2BD1cXotVagtLw%3D
26. MC Hsieh ML Yu WL Chuang, et al. 2000 Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C Eur J Endocrinol 142 431 437 10802518 10.1530/eje.0.1420431 1:CAS:528:DC%2BD3cXjslemu7o%3D
27. MY Hsieh CY Dai LP Lee, et al. 2008 Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C J Clin Pathol 61 333 337 17545561 10.1136/jcp.2006.046276 1:CAS:528:DC%2BD1cXkt1yjtrs%3D
28. MG Ghany DB Strader DL Thomas LB Seeff 2009 Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 1335 1374 19330875 10.1002/hep.22759 1:CAS:528:DC%2BD1MXkslWjs7o%3D
29. CY Dai CK Ho JF Huang, et al. 2010 Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan J Hepatol 52 160 166 20034694 10.1016/j.jhep.2009.11.017
30. JF Yang CI Lin JF Huang, et al. 2010 Viral hepatitis infections in southern Taiwan: a multicenter community-based study Kaohsiung J Med Sci 26 461 469 20837342 10.1016/S1607-551X(10)70073-5
31. SD Lee ML Yu PN Cheng, et al. 2005 Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan J Viral Hepat 12 283 291 15850469 10.1111/j.1365-2893.2005.00590.x
32. ML Yu CY Dai ZY Lin, et al. 2006 A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan Liver Int 26 73 81 16420512 10.1111/j.1478-3231.2005.01196.x 1:CAS:528:DC%2BD28XisFCmu70%3D